- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06565195
En randomisert, dobbeltblind, placebokontrollert, enkeltstigende dosestudie i friske frivillige og en dobbeltblind, placebokontrollert, multippelstigende dosestudie hos pasienter med Parkinsons sykdom for å evaluere sikkerhet, tolerabilitet og PK /PD av LY3962681 (PROSPECT-PD)
En randomisert, dobbeltblind (sponsor-ublindet), placebokontrollert, enkelt-stigende dose-studie i friske frivillige og en dobbeltblind (sponsor-ublindet), placebo-kontrollert, multippel-stigende dose-studie i pasienter med Parkinson Sykdom for å evaluere sikkerheten, toleransen og PK/PD til LY3962681
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of LY3962681 in healthy volunteers and patients with Parkinson's disease.
The study consists of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Dose (MAD) study.
During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid [aCSF]) administered intrathecally (into the spinal fluid). During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered intrathecally (into the spinal fluid), 12 to 24 weeks apart.
- The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 dosing days, 12 to 24 weeks apart.
- The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks after Dose 2.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Prevail Therapeutics
- Telefonnummer: 917-336-9310
- E-post: Prevail.Patients@lilly.com
Studiesteder
-
-
Colorado
-
Englewood, Colorado, Forente stater, 80113
- Har ikke rekruttert ennå
- CenExel
-
Ta kontakt med:
- Anahaga Champakanath
- Telefonnummer: (303) 867-5468
- E-post: a.champakanath@cenexel.com
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Har ikke rekruttert ennå
- Institute for Neurodegenerative Disorders
-
Ta kontakt med:
- Anna Carberry
- Telefonnummer: (475) 318-8250
- E-post: clinicrecruitment@indd.org
-
-
Florida
-
Naples, Florida, Forente stater, 34105
- Rekruttering
- Aqualane Clinical Research
-
Ta kontakt med:
- Christopher Webb
- Telefonnummer: (239) 529-6780
- E-post: christopher@aqualaneresearch.com
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Har ikke rekruttert ennå
- Northwestern University Feinberg School of Medicine Dept of Neurology
-
Ta kontakt med:
- Camryn Butze
- Telefonnummer: (312) 503-6824
- E-post: camryn.butze@northwestern.edu
-
-
Michigan
-
Farmington Hills, Michigan, Forente stater, 48334
- Rekruttering
- Quest Research Institute - Alcanza
-
Ta kontakt med:
- Denise Morgott
- Telefonnummer: (248) 957-8940
- E-post: Denise.Morgott@questri.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Har ikke rekruttert ennå
- University of Pennsylvania, Dept of Neurology
-
Ta kontakt med:
- Spriha Thapa
- Telefonnummer: (267) 610-8822
- E-post: Spriha.Thapa@PennMedicine.upenn.edu
-
-
Texas
-
Austin, Texas, Forente stater, 78744-1625
- Fullført
- Austin Clinic PPD
-
-
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Rekruttering
- Ehime University Hospital
-
Ta kontakt med:
- Akemi Fujita
- Telefonnummer: 089-960-5913
- E-post: fujita.akemi.aw@ehime-u.ac.jp
-
-
Oita Prefecture
-
Yufu, Oita Prefecture, Japan, 879-5593
- Har ikke rekruttert ennå
- Oita University Hospital
-
Ta kontakt med:
- Tomoko Matsuda
- Telefonnummer: 097-586-6114
- E-post: to-matsu@oita-u.ac.jp
-
-
Tokyo
-
Hachiōji, Tokyo, Japan, 192-0071
- Rekruttering
- P-One Clinic, Keikokai Medical Corporation
-
Ta kontakt med:
- Yukari Kaneko
- Telefonnummer: 080-8759-9604
- E-post: kaneko@keikokai-gr.or.jp
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Nederland, 6525 GA
- Har ikke rekruttert ennå
- Radboud Universitair Medisch Centrum
-
Ta kontakt med:
- Bas Bloem
-
-
Provincie Groningen
-
Groningen, Provincie Groningen, Nederland, 9713 GZ
- Har ikke rekruttert ennå
- CTC Netherlands BV
-
Ta kontakt med:
- Khalid Abd-Elaziz
- Telefonnummer: 31503055480
- E-post: khalid.abdelaziz@ctc-netherlands.com
-
-
-
-
Hampshire
-
Southampton, Hampshire, Storbritannia, SO16 6TH
- Har ikke rekruttert ennå
- Southampton General Hospital, NHS Trust
-
Ta kontakt med:
- Danny Pratt
- Telefonnummer: 0044 2381204989
- E-post: danny.pratt@uhs.nhs.uk
-
-
Oxfordshire
-
Oxford, Oxfordshire, Storbritannia, OX3 9DU
- Har ikke rekruttert ennå
- John Radcliffe Hospital
-
-
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Tyskland, 40225
- Har ikke rekruttert ennå
- Universitätsklinikum Düsseldorf
-
Ta kontakt med:
- Abraham Nsah Ndifon
- Telefonnummer: +492118108262
- E-post: abrahamnsah.ndifon@med.uni-duesseldorf.de
-
Münster, North Rhine-Westphalia, Tyskland, 48149
- Har ikke rekruttert ennå
- Universitätsklinikum Münster
-
Ta kontakt med:
- Isabel Aymanns
- Telefonnummer: +492518344427
- E-post: isabel.aymanns@ukmuenster.de
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participant is overtly healthy as determined by medical evaluation. Rescreening is allowed in this study.
- A Montreal Cognitive Assessment score greater than or equal to 24.
MAD study only
- Stable use of background medications at least 8 weeks prior to IP administration, including but not limited to those used for treatment of Parkinson's disease (including deep brain stimulation), and the investigator must expect that participant can tolerate a minimum of 6 months without dose adjustment.
- Participant has a diagnosis of Parkinson's disease per UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
- Modified Hoehn and Yahr Stage 1 to 2.5 in the practically defined OFF state.
- A positive result on CSF alpha-synuclein Seed Amplification Assay. (A prior positive result [within 1 year of screening] accepted with sponsor approval if patient did not participate in another Parkinson's disease clinical trial during this period.) (US and Japan only)
- UPSIT score of 20 percentile or less, corrected for age and sex (EU and UK only).
- An abnormal DaT-SPECT consistent with parkinsonism. (History of an abnormal DaTSPECT with the report confirmed by study investigator will be accepted.)
- For participants not taking Parkinson's disease medications, not expected to initiate treatment within 6 months.
- Have a body weight within 40 kg (88 pounds) to 110 kg (242 pounds), inclusive, and body mass index within the range of 17 to 34 kg/m^2, inclusive.
Exclusion Criteria:
- MAD study only: Significant neurological disease affecting the central nervous system other than Parkinson's disease that may be a cause for the participant's clinical symptoms or may confound study objectives.
- Current concomitant disease or serious or unstable illnesses, including central nervous system (SAD study only), cardiovascular, hepatic, renal, gastroenterology, respiratory, endocrinologic, neurologic (MAD study only: other than Parkinson's disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the participant.
- Participant is generally frail or has any medical disorders that, in the opinion of the investigator, could interfere with study-related procedures (including safe performance of IT injection or LP), such as prohibitive spinal diseases, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, or increased intracranial pressure.
- Have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
- MAD study only: Treatment with continuous intestinal delivery Parkinson's disease medication (for example, Duodopa).
- MAD study only: Significant renal impairment (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m^2).
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LY3962681 (SAD)
Single ascending dose of LY3962681 administered intrathecally (IT) to healthy volunteers. |
IT injection |
|
Placebo komparator: Placebo (SAD)
Single ascending dose of placebo (aCSF) administered intrathecally (IT) to healthy volunteers. |
IT injection |
|
Eksperimentell: LY3962681 (MAD)
Multiple ascending doses of LY3962681 administered IT to participants with Parkinson's disease. |
IT injection |
|
Placebo komparator: Placebo (MAD)
Multiple ascending doses of placebo (aCSF) administered IT to participants with Parkinson's disease. |
IT injection |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst av alvorlige bivirkninger (SAE)
Tidsramme: Opptil 76 uker
|
Opptil 76 uker
|
|
Forekomst av akutte behandlingsbivirkninger (TEAE)
Tidsramme: Opptil 76 uker
|
Opptil 76 uker
|
|
Antall seponeringer på grunn av uønskede hendelser (AE)
Tidsramme: Opptil 76 uker
|
Opptil 76 uker
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
LY3962681 Maksimal observert konsentrasjon (Cmax)
Tidsramme: Opptil 76 uker
|
Opptil 76 uker
|
|
Endring fra baseline i CSF totalt alfa-synuklein
Tidsramme: Opptil 76 uker
|
Opptil 76 uker
|
|
LY3962681 area under the concentration versus time curve (AUC)
Tidsramme: Up to 76 weeks
|
Up to 76 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Travis Lewis, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- J5F-MC-OOAA
- 2024-513411-27-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .